Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: The use of 2 × 2000 mg myo-inositol +2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with polycystic ovary syndrome (PCOS). In addition, PCOS is one of the pathological factors involved in the failure of in vitro fertilization (IVF). Typically, PCOS patients suffer of poor quality oocytes. Patients and methods: In an open, prospective, non-blinded, non-comparative observational study, 3602 infertile women used myo-inositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myo-inositol +2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. In the second part of this trial it was investigated if the combination of myo-inositol + folic acid was able to improve the oocyte quality, the ratio between follicles and retrieved oocytes, the fertilization rate and the embryo quality in PCOS patients undergoing IVF treatments. Twenty-nine patients with PCOS, underwent IVF protocols for infertility treatment and were randomized prospectively into two groups. Group A (placebo) with 15 patients and group B (4000 mg myo-inositol +400 μg folic acid per day) with 14 patients were evaluated. The patients of group B used 2 months’ myo-inositol + folic acid before starting the IVF protocol. For statistically analyses Student’s t-test was performed. Results: Seventy percent of the women had a restored ovulation, and 545 pregnancies were observed. This means a pregnancy rate of 15.1% of all the myo-inositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/mL to 43.3 ng/mL and progesterone from 2.1 ng/mL to 12.3 ng/mL in the mean after 12 weeks of treatment (p < 0.05) Student’s t-test. No relevant side effects were present among the patients. The women in the IVF treatment the group A showed a higher number of retrieved oocytes than group B. Nevertheless, the ratio follicle/retrieved oocyte was clearly better in the myo-inositol group (= group B). Out of the 233 oocytes collected in the myo-inositol group, 136 where fertilized whereas only 128 out of 300 oocytes were fertilized in the placebo group. With regards to the oocytes quality, better data were obtained in the myo-inositol group. More metaphase II and I oocytes were retrieved in relation to the total number of oocytes, when compared with the placebo group. Also, more embryos of grade I quality were observed in the myo-inositol group than in the placebo group. The duration of stimulation was 9.7 days (±3.3) in the myo-inositol group and 11.2 (±1.8) days in the placebo group and the number of used follicle-stimulating hormone (FSH) units was lower in the myo-inositol group in comparison to the placebo group: 1850 FSH units (mean) versus 1850 units (mean). Discussion: Myo-inositol has proven to be a new treatment option for patients with PCOS and infertility. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported using metformin as an insulin sensitizer. No moderate to severe side effects were observed when myo-inositol was used at a dosage of 4000 mg per day. In addition, our evidence suggests that a myo-inositol therapy in women with PCOS results in better fertilization rates and a clear trend to a better embryo quality. As by the same way the number of retrieved oocytes was smaller in the myo-inositol group, the risk of a hyperstimulation syndrome in these patients can be reduced. Therefore, myo-inositol also represents an improvement in IVF protocols for patients with PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 2×
“In human follicular fluids, higher concentrations of MI provide a marker of good-quality oocytes [31], [36], [45].”
BackgroundRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“To reach a general agreement on diagnostic criteria many investigations have focused, independently of the above-mentioned disorders on the impaired glucose tolerance, which affects 30–40% of women with PCOS [5] and on insulin resistance.”
BackgroundOvulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“It was shown that inositol administration increases the action of insulin in patients with PCOS, thereby improving ovulatory function and decreasing serum testosterone concentration [21], [33], [34], [35], [36].”
BackgroundGenazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 1×
“Hyperinsulinemia due to insulin resistance occurs in up to 80% of women with PCOS and central obesity as well as in 30–40% of lean women diagnosed with this syndrome [6], [7], [8].”
BackgroundEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188 · cited 2×
“[33] could show that in patients with PCOS the treatment with myo-inositol and folic acid, but not folic acid alone, reduced germinal vesicles and degenerated oocytes at ovum pick-up without compromising total number of retrieved oocytes.”
BackgroundSun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144 · cited 1×
“Some other studies have shown the efficacy of myo-inositol in the improvement of the fertility of PCOS patients due to its improvement of the insulin resistance in these women [41], [42], [43].”
ResultReflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106 · cited 1×
“The paradox theory published and discussed by Nestler and Carlomagno [27], [28] suggested that D-chiro-inositol, in not physiological high dosages, had a negative impact on the quality of oocytes of PCOS women, as the ovarian epimerase function is not altered in PCOS patients so that the myo-inositol levels in the fol…”
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · cited 1×
“[40], where a comparison between the administration of myo-inositol (2 × 2000 g + 200 μg per day) and metformin (1500 mg per day) in women with a PCOS was performed, it could be shown that the number of pregnancies was clearly higher in the myo-inositol group than in the metformin group of patients.”
Background
Cited by
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
Ashkar, F., Rezaei, S., Salahshoornezhad, S., Vahid, F., Gholamalizadeh, M., Dahka, S. M., & Doaei, S. (2020) · BioMolecular Concepts · doi:10.1515/bmc-2020-0005 · Cited by 68
Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00933-y · Cited by 17
Metadata
- Authors
- Regidor, P.-A., Schindler, A. E., Lesoine, B., & Druckman, R.
- Venue
- Hormone Molecular Biology and Clinical Investigation
- Publisher
- Walter de Gruyter GmbH
- Published
- 2018-03-02
- Volume
- 34
- Issue
- 2
- ISSN
- 1868-1883 (ISSN-L)
- 1868-1891
- OpenAlex
- W2796797549
- Cited by
- 74
- References
- 10
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. https://app.cochat.ai/papers/10.1515/hmbci-2017-0067
- The paper
- Regidor, P.-A., Schindler, A. E., Lesoine, B., & Druckman, R. (2018). Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Hormone Molecular Biology and Clinical Investigation. https://doi.org/10.1515/hmbci-2017-0067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.